Market revenue in 2023 | USD 3,338.2 million |
Market revenue in 2030 | USD 4,953.0 million |
Growth rate | 5.8% (CAGR from 2023 to 2030) |
Largest segment | Peripheral stents |
Fastest growing segment | Hemodynamic Flow Alteration Devices |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | PTA Balloons, Catheters, Endovascular Aneurysm Repair Stent Grafts, Plaque Modification Devices, Peripheral Accessories, Inferior Vena Cava Filters, Hemodynamic Flow Alteration Devices, Peripheral Stents |
Key market players worldwide | Abbott Laboratories, Edwards Lifesciences Corp, Medtronic PLC, St. Jude Medical, Teleflex Inc, Philips, Boston Scientific Corp, Cook Group, Covidien, AngioScore |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peripheral vascular devices market will help companies and investors design strategic landscapes.
Peripheral stents was the largest segment with a revenue share of 20.65% in 2023. Horizon Databook has segmented the U.S. peripheral vascular devices market based on pta balloons, catheters, endovascular aneurysm repair stent grafts, plaque modification devices, peripheral accessories, inferior vena cava filters, hemodynamic flow alteration devices, peripheral stents covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. has a pivotal role in peripheral vascular devices market, characterized by a dynamic regional landscape featuring substantial growth and notable technological progress. The demand for peripheral vascular devices is growing due to several factors such as rising incidence of cardiovascular diseases and an increasing number of clinical trials exploring stent applications in PAD.
For instance, in March 2024, BD initiated a clinical trial for its experimental vascular-covered stent in individuals diagnosed with PAD. The trial aims to enroll 315 patients and assess the safety and efficacy of the self-expanding nitinol implant featuring a fluoropolymer coating.
Although BD currently markets various medical devices catering to PAD, such as the self-expanding Lifestent, the company has recognized the demand for a robust stent capable of effectively navigating lesions and maintaining proximity to the vessel wall. Such initiatives are expected to further contribute to the market expansion.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. peripheral vascular devices market, including forecasts for subscribers. This country databook contains high-level insights into U.S. peripheral vascular devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account